Rechallenge with TKI in NSCLC patients with EGFR mutations relies on the hypothesis that only a fraction of the EGFR-mutant tumor cells acquires a second genetic alteration that determines resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.